Bionorica SE
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1933-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.bionorica.de
Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)
Phase 3
Completed
- Conditions
- Urinary Tract Infection
- Interventions
- Drug: Canephron® N
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 125
- Registration Number
- NCT01478620
- Locations
- 🇺🇦
Kiev Regional City Hospital, Kiev, Ukraine
Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome
Phase 3
Completed
- Conditions
- Cyclic MastodyniaPremenstrual Syndrome
- Interventions
- Drug: VAC BNO 1095 film coated tablets
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 191
- Registration Number
- NCT01309113
- Locations
- 🇨🇿
Gynekologicko-porodnická ambulance, Olomouc, Czech Republic
Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 386
- Registration Number
- NCT01146860
- Locations
- 🇩🇪
Dr. Rainer Jund, Specialist in Otorhinolaryngology, Puchheim, Germany
© Copyright 2025. All Rights Reserved by MedPath